Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alaska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alaska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alaska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

John Botson (NPI 1881700334)

Field	Value
Entity Type	Individual
Organization	John Botson
Address	3801 Lake Otis Pkwy Ste 300
City	Anchorage
State	AK
ZIP	99508
Taxonomy	Rheumatology Physician
NPI Enumerated	August 21, 2006

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

This provider’s revenue is effectively single-payer Medicare: Total Medicare revenue is $1.8M and there is no Medicaid billing on file. The absence of Medicaid activity suggests the provider’s commercial and Medicaid exposure is minimal or not captured in this dataset, concentrating observed reimbursement risk on Medicare flows.

NPI tenure indicates long-standing enrollment: NPI enumerated on 2006-08-21 (~20 years ago), signaling roughly two decades of Medicare participation and likely established referral relationships and operational workflows. That tenure is consistent with the mix of recurring biologic administrations and office-based services reported.

Clinical and service-line profile centers on biologic infusion/injection therapy consistent with a Rheumatology Physician taxonomy: the largest Medicare revenue items are drug/injection codes such as J1745 (infliximab), J3262 (tocilizumab), J3111 (romosozumab) and J9312 (rituximab), and the presence of 77080 (DXA) and J0897 (denosumab) supports a mix of inflammatory disease management and bone-health services. This code mix indicates the practice operates substantial in-office or on-site infusion/administration capacity rather than being solely an outpatient evaluation clinic.

Revenue concentration is high: the top three Medicare codes (J1745, J3262, J3111) account for 61.0% of this provider’s total Medicare revenue, with J1745 $469.8K (25.8%), J3262 $331.7K (18.2%), and J3111 $310.8K (17.0%). Such concentration around a small set of high-cost injectable therapies means changes in utilization, reimbursement, or drug sourcing could materially affect total Medicare receipts.

Competitive standing is mixed by code: for J1745 the provider ranks #19 of 1352 nationally (99th percentile; extreme outlier), indicating an outsized national role in billing for infliximab. By contrast, J3262 ranks #146 of 618 (76th percentile) and J3111 ranks #116 of 970 (88th percentile), both characterized as typical or unremarkable relative to national peers, so dominance appears concentrated specifically in infliximab administrations rather than across all biologic therapies.

Infusion- and chemotherapy-related services are above typical national volumes for several procedural codes, underscoring a treatment-delivery model: 96413 shows $63.5K (3.5% of Medicare revenue) and ranks #461 of 7514 (94th percentile; notably above typical national volume), and 96415 shows $9K (0.5%) and ranks #180 of 4959 (96th percentile; notably above typical national volume). These elevated percentiles for infusion add-on and chemotherapy administration codes reinforce that the practice provides repeated prolonged infusions in-office.

Routine outpatient evaluation and ancillary services are present but not dominant: 99214 accounts for $49.6K (2.7%) and ranks in the 89th percentile nationally, and 99215 accounts for $21.2K (1.2%) at the 85th percentile, indicating steady office-based continuity care alongside infusion work. Ancillary diagnostics such as 77080 (DXA) contribute as expected for a rheumatology-focused practice, with 77080 at $19.6K (1.1%) and a 92th percentile rank, consistent with osteoporosis management offered on-site.

Operational risk and business implication: heavy dependence on a small set of high-cost injectable drugs—especially J1745 where the provider is an extreme outlier—creates concentration risk for revenue and operational throughput. Given the provider’s single-payer Medicare footprint here and top-three concentration of 61.0%, payer policy changes, drug supply shifts, or competitive entry for infusion services could have outsized effects on this practice’s Medicare revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

30 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1745	Injection, infliximab, excludes biosimilar, 10 mg	18,070	$30	$469.8K
J3262	Injection, tocilizumab, 1 mg	66,330	$10	$331.6K
J3111	Injection, romosozumab-aqqg, 1 mg	38,850	$10	$310.8K
J9312	Injection, rituximab, 10 mg	4,770	$60	$305.2K
J1602	Injection, golimumab, 1 mg, for intravenous use	10,040	$10	$110.5K
J0897	Injection, denosumab, 1 mg	4,800	$20	$86.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	580	$110	$63.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	480	$100	$49.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	130	$160	$21.2K
77080	The provider performs an imaging procedure, called dual–energy X–ray absorptiometry (DXA), of one or more bony areas on the trunk to determine the bone mineral density (BMD) and whether the patient…	450	$40	$19.6K

Showing 1–10 of 30

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 30 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alaska Distribution

John Botson — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alaska

Full comparison — all codes billed, vs. state median

30 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3262	1	10	66,330	$1	$310.9K
J1745	1	10	5,220	$30	$235K
J3111	1	10	22,470	$10	$192.9K
J9312	1	10	2,330	$60	$168.4K
J1602	1	10	10,040	$10	$106.1K
J0897	12	30	2,700	$20	$82.7K
96413	3	20	230	$110	$30.2K
99214	74	1,210	90	$100	$16.2K
99215	60	400	40	$150	$11K
99205	78	140	30	$190	$7.4K

Showing 1–10 of 30

Related Providers

Other providers that share a Tax Identification Number (TIN) with John Botson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Orthoalaska, LLC	AK	Orthopaedic Surgery Physician	$0	$5.8M
Jeff Peterson	WA	Rheumatology Physician	$1M	$0
Bryan Haughom	AK	Orthopaedic Surgery Physician	$525.6K	$0
Laura Luebke	AK	Medical Physician Assistant	$428.6K	$0
Ryan Ragle	AK	Rheumatology Physician	$413.8K	$0
James Eule	AK	Orthopaedic Surgery of the Spine Physician	$400.6K	$0
Mark Flanum	AK	Orthopaedic Surgery of the Spine Physician	$270K	$0
Derrick Foge	AK	Orthopaedic Surgery of the Spine Physician	$268.1K	$0
Thomas Paynter	AK	Orthopaedic Surgery Physician	$260.9K	$0
Curtis Mina	AK	Orthopaedic Surgery of the Spine Physician	$236.4K	$0

Nearby Providers

Other providers in the same ZIP code as John Botson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alaska Native Tribal Health Consortium	AK	General Acute Care Hospital	$0	$397.1M
Providence Health & Services Washington	AK	General Acute Care Hospital	$0	$161.5M
Southcentral Foundation	AK	Community Health Clinic/Center	$0	$130.3M
Alaska Native Tribal Health Consortium	AK	Transportation Broker	$0	$65.5M
The Arc Of Anchorage	AK	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$50.8M
Good Samaritan Care Services	AK	In Home Supportive Care Agency	$0	$46.1M
Alaska Native Tribal Health Consortium	AK	General Acute Care Hospital	$0	$33.1M
Galen Hospital Alaska, Inc.	AK	General Acute Care Hospital	$0	$31.8M
Anchorage Community Mental Health	AK	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$31.7M
Patient Housing At Anmc	AK	General Acute Care Hospital	$0	$31M

John Botson — Billing Profile & Reimbursement Data

Sign up for John Botson — Billing Profile & Reimbursement Data policy alerts

John Botson — Billing Profile & Reimbursement Data

Sign up for John Botson — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References